This Biotech Stock Soared 116% in 2024, but Is It a Buy in 2025?
One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...
Investing6d
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data
In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only ...
Viking Therapeutics: Cooling Market Sentiments Surrounding GLP1s - Much Uncertainties Ahead
Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...
Investing6d
Viking Therapeutics stock gains traction with standout dual-agonist VK2735 efficacy data
In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets ...
Promising Clinical Developments and Strategic Initiatives Drive Buy Rating for Viking Therapeutics
BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...
24/7 Wall St. on MSN6d
Billionaire Sold Palantir and Is Buying This Stock That Could Soar 237%, According to a Wall Street Expert
Palantir Technologies (NASDAQ:PLTR) has been described as the best pure-play stock in artificial intelligence. The market ...
What's next for Viking Therapeutics? Here's how the company can scale up.
Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...